Navigation Links
FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable

CHICAGO, Dec. 12/PRNewswire-FirstCall/ --The Female Health Company (NYSE Alternext: FHC) has announced that the U.S. Food and Drug Administration's (FDA) Obstetrics and Gynecology Devices Advisory Committee has unanimously voted that the company's second-generation female condom, the FC2 Female Condom(R), is approvable with a single condition.

The Advisory Committee voted 15-0 that the product is approvable with the condition that the FC2 Female Condom's instructions for use continue to follow use instructions for the FC Female Condom(R) (FC1 Female Condom) and appropriately identify the study that was performed to establish the comparable safety and effectiveness of FC2 with FC1.

The FDA is not bound by the committee's recommendation, but it takes its advice into consideration when reviewing obstetric and gynecologic devices.

"We are very pleased with today's outcome and look forward to working with the FDA as it continues to review our application for the FC2 Female Condom," said Dr. Mary Ann Leeper, FHC's Senior Strategic Advisor. "We believe that FHC's second-generation female condom can strengthen the fight against AIDS by expanding affordable access to a woman-initiated HIV prevention method."

The company filed the FC2 Female Condom Pre-market Approval Application (PMA) with the FDA on January 7, 2008 and has been working with FDA as it reviewed the application.

The company's first-generation FC1 Female Condom received FDA approval for distribution in the United States in 1993. The FC1 Female Condom is also included in the World Health Organization's (WHO) essential products list for distribution by United Nations (UN) agencies. Since its approval, 165 million FC1 Female Condoms have been distributed in 142 countries.

The FC2 Female Condom data has been reviewed by other public agencies, including the European Union, India, Brazil and the World Health Organization (WHO). In 2006, the WHO agreed that the FC2 Female Condom does perform in the same manner as the FC1 Female Condom and recommended that the FC2 Female Condom can be purchased by UN agencies. Since then, over 22 million FC2 female condoms have been distributed in 77 countries.

Performance of FC2 Female Condom in Clinical Trial

FHC presented data from a randomized, double-blind, crossover, comparative trial with the FC1 Female Condom. The FC1 Female Condom is currently distributed in over 100 countries, including the U.S. The FC2 Female Condom, which looks very similar to the FC1 Female Condom, was developed to expand access to women at risk of HIV and STIs by lowering the cost of the product through the introduction of a more efficient manufacturing process. The clinical trial was conducted in 2004 by the Reproductive Health and HIV Research Unit of the University of Witwatersrand in South Africa. Over 200 women participated in the study. The results of the study showed that the FC2 Female Condom is safe and that the risk of failure during use was equivalent to FC1. Results from the study were originally published in the journal Contraception. (See Contraception 73 (2006) 386- 393.)

Unintended Pregnancy and HIV/STI Transmission in the U.S.

Unintended pregnancy and the transmission of HIV and other STIs remain significant public health challenges in the U.S. According to the Centers for Disease Control and Prevention (CDC), approximately one-half of pregnancies in the U.S. were unintended in 2001, and contraception methods provided by federally funded family planning programs (male condoms, female condoms, the Pill, and IUDs) prevent an estimated 1.3 million unintended pregnancies each year.

Over the past two decades, the proportion of women among all people living with HIV/AIDS (PLHIV) in the U.S. has more than tripled -- from 8 percent of PLHIV in 1985 to 26 percent in 2007. HIV infection has emerged as the leading cause of death for African American women aged 25-34, high-risk heterosexual contact is responsible for 80 percent of new HIV infections among American women, and one in four young adults aged 15-20 years contracts a sexually transmitted infection each year.

In this context, expanded access to the female condom -- the only safe, effective, and available woman-initiated prevention method currently available -- can provide women and men with more options to practice safer sex and prevent unintended pregnancy.

About The Female Health Company

The Female Health Company (FHC), headquartered in Chicago, IL, is the maker of the FC1 Female Condom and the FC2 Female Condom, woman-initiated prevention methods offering dual protection against sexually transmitted infections, including HIV/AIDS, and unintended pregnancy. FHC was created as a worldwide company in February 1996 with the purchase of Chartex Resources, Ltd., the holder of exclusive worldwide rights to the FC1 Female Condom. The Company holds exclusive product and technology patents for the FC1 Female Condom in the U.S., Australia, Brazil, Canada, France, Germany, Italy, Spain, the United Kingdom, the People's Republic of China, South Korea and Japan. Patents are pending for the FC2 Female Condom. FHC is the sole worldwide manufacturer and marketer of the FC1 Female Condom and the FC2 Female Condom.

The Female Health Company and its partners currently market the Female Condom under FC Female Condom(R), FC2 Female Condom(R), Reality(R), Femidom(R), Femy(R), and Care(R) in the rest of the world.

For more information about the Female Health Company, visit the Company's website at and If you would like to be added to the Company's e-mail alert list, please send an email to

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

The statements in this release which are not historical fact are "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release may be identified by the use of forward-looking words or phrases such as "anticipate," "believe," "could," "expect," "intend," "may," "planned," "potential," "should," "will," "would" or the negative of those terms or other words of similar meaning. These statements are based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, and are made as of the date of this release. The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events, developments or circumstances. Such forward-looking statements are inherently subject to known and unknown risks and uncertainties. The Company's actual results and future developments could differ materially from the results or developments expressed in, or implied by, these forward-looking statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the following: product demand and market acceptance; competition in the Company's markets and the risk of new competitors and new competitive product introductions; the Company's reliance on its international partners in the consumer sector and on the level of spending on the female condom by country governments, global donors and other public health organizations in the global public sector; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company's production capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communication and Securities and Exchange Commission filings, including the Company's Form 10-KSB for the fiscal year ended September 30, 2007. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

SOURCE Female Health Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
2. AANMA Provides Commentary to FDA Advisory Committees Reviewing Benefit-Risk Assessment of 12 Hour Bronchodilators
3. New Health Care Advisory Board to Advise PNC on Billing, Payments and Financial Management
4. PharmMD Expands Advisory Board
5. U.S. Labor Secretary Elaine L. Chao announces new membership of OSHA advisory committee
6. Pennsylvania DEP Directs Shadyside Water Supply to Issue Boil Water Advisory
7. Advisory Vote Begins on California Long-Term Care Local
8. Governors Advisory Council on Physical Fitness and Sports Awards Presented by Health
9. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2008 Third Quarter Results
10. Medipacs Appoints Advisory Board Members
11. Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board
Post Your Comments:
(Date:11/27/2015)... ... 2015 , ... The moment you stop improving is the ... the needs of advisers and clients but going above and beyond to find ... service. However, there's always room for improvement, which is why the entire Consulting ...
(Date:11/27/2015)... ... 2015 , ... CBD College is proud to announce that on ... accreditation to its Diagnostic Medical Sonography program. CBD College is honored to join this ... colleges and universities in the state of California make the cut. CBD College is ...
(Date:11/27/2015)... ... 2015 , ... Dr. Thomas Dunlap and Dr. Patrick Coleman ... with Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , ... in similar ways and require time-critical intervention to avoid large area heart damage and ...
(Date:11/27/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk ... Term Support) into its Q-Suite 5.10 product line. , Making the change to ... of Asterisk that will receive not only security fixes, but feature and bug ...
(Date:11/26/2015)... ... 2015 , ... Inevitably when people think Thanksgiving, they also think Holiday sales ... Black Friday and Cyber Monday massage chair sales to receive the best ... low to find the best massage chair deals, they can see all of the ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015 AAIPharma Services Corp./Cambridge Major Laboratories, ... least $15.8  Million to expand its laboratories and ... . The expansion will provide additional office space ... demands of the pharmaceutical and biotechnology markets. ... provide up to 40,000 square feet of expanded ...
(Date:11/25/2015)... , Nov. 25, 2015  ARKRAY USA ... continues to provide evidence demonstrating the accuracy of its ... Congress on Insulin Resistance, Diabetes and Cardiovascular Disease in ... both the Company,s GLUCOCARD ® 01 meter and ... accuracy requirements. The ability to accurately measure glucose levels ...
(Date:11/25/2015)... 25, 2015 Kitov Pharma ... KTOV), a biopharmaceutical company focused on the development of ... conditions, today announced the closing of its previously announced ... ADSs ), each representing 20 ordinary shares of the ... The ADSs and warrants were issued in a fixed ...
Breaking Medicine Technology: